Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.05 Analyst target: $17.00 Upside: 319.75%
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.